These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1003103)

  • 1. The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo.
    Cancro M; Potter M
    J Exp Med; 1976 Dec; 144(6):1554-67. PubMed ID: 1003103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of adherent peritoneal exudate cells (APECs) and their products on the RPC-5 plasmacytoma growth in vitro.
    Salwa J
    Arch Immunol Ther Exp (Warsz); 1990; 38(3-4):267-74. PubMed ID: 2102659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of plasmacytoma development in BALB/c mice by indomethacin.
    Potter M; Wax JS; Anderson AO; Nordan RP
    J Exp Med; 1985 May; 161(5):996-1012. PubMed ID: 3989472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of adherent peritoneal exudate cells on plasmacytoma growth in BALB/c mice.
    Salwa J
    Arch Immunol Ther Exp (Warsz); 1990; 38(3-4):287-90. PubMed ID: 2102661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transplantation of primary plasma cell tumor without 2,6,10,14- tetramethylpentadecane (pristane) treatment of the hosts.
    Platica M; Bojko C; Hollander VP
    Cancer Res; 1980 Mar; 40(3):579-81. PubMed ID: 7471077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The enhancement of growth of a syngeneic plasmacytoma in BALB/c mice by pristane priming is not due to immunosuppressive effects on antibody-forming cell or mitogen-responsive splenocytes.
    Ruiz-Bravo A; Perez M; Jimenez-Valera M
    Immunol Lett; 1995 Jan; 44(1):41-4. PubMed ID: 7721342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pristane induces an indomethacin inhibitable inflammatory influx of CD4+ T cells and IFN-gamma production in plasmacytoma-susceptible BALB/cAnPt mice.
    McDonald AH; Degrassi A
    Cell Immunol; 1993 Jan; 146(1):157-70. PubMed ID: 8425224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intraperitoneal pristane on established immunity to the adj-PC-5 plasmacytoma.
    Potter M; Walters JL
    J Natl Cancer Inst; 1973 Sep; 51(3):875-81. PubMed ID: 4743559
    [No Abstract]   [Full Text] [Related]  

  • 9. The bisphosphonate zoledronic acid inhibits the development of plasmacytoma induced in BALB/c mice by intraperitoneal injection of pristane.
    Avcu F; Ural AU; Yilmaz MI; Ozcan A; Ide T; Kurt B; Yalcin A
    Eur J Haematol; 2005 Jun; 74(6):496-500. PubMed ID: 15876253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of the plasmacytomagenic alkane pristane (2,6,10,14-tetramethylpentadecane) in mice.
    Janz S; Shacter E
    Cancer Biochem Biophys; 1995 Jun; 15(1):25-34. PubMed ID: 8536217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: inhibition by indomethacin.
    Shacter E; Arzadon GK; Williams J
    Blood; 1992 Jul; 80(1):194-202. PubMed ID: 1611085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens.
    Potter M; Wax JS
    J Natl Cancer Inst; 1983 Aug; 71(2):391-5. PubMed ID: 6576197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice.
    Potter M; Morrison S; Wiener F; Zhang XK; Miller FW
    J Natl Cancer Inst; 1994 Jul; 86(14):1058-65. PubMed ID: 8021954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain.
    Potter M; Wax J; Jones GM
    Blood; 1997 Jul; 90(1):260-9. PubMed ID: 9207461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbation of B cell genesis in the bone marrow of pristane-treated mice. Implications for plasmacytoma induction.
    Rico-Vargas SA; Potter M; Osmond DG
    J Immunol; 1995 Mar; 154(5):2082-91. PubMed ID: 7868885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Damage to surface membrane of Schistosoma mansoni by pristane (2, 6, 10, 14 tetramethyl pentadecane) and other hydrophobic compounds.
    Kusel JR; Stones L; Tetley L
    Parasitology; 1980 Feb; 80(1):83-94. PubMed ID: 7383711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growth characteristics of an ascitic plasmacytoma (MP 5563) terminating by fistulous communication with the blood-stream.
    Fakhri O
    Br J Cancer; 1970 Jun; 24(2):389-94. PubMed ID: 5456739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide and pristane-induced peritoneal exudate requirements for plasma tumor cell colony formation.
    Platica M; Bojko C; Clincea R; Hollander V
    J Natl Cancer Inst; 1982 Feb; 68(2):325-8. PubMed ID: 6950164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gas chromatographic-mass spectrometric investigation of four commercial pristane (2.6.10.14-tetramethylpentadecane) preparations used for plasmacytoma induction in BALB/c mice.
    Janz S; Birkenfeld T; Herzschuh R; Storch H
    Arch Geschwulstforsch; 1989; 59(6):415-22. PubMed ID: 2596957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.